vs

Side-by-side financial comparison of Altimmune, Inc. (ALT) and FOCUS UNIVERSAL INC. (FCUV). Click either name above to swap in a different company.

FOCUS UNIVERSAL INC. is the larger business by last-quarter revenue ($35.3K vs $26.0K, roughly 1.4× Altimmune, Inc.). On growth, Altimmune, Inc. posted the faster year-over-year revenue change (420.0% vs 214.5%). FOCUS UNIVERSAL INC. produced more free cash flow last quarter ($-1.4M vs $-67.5M). Over the past eight quarters, Altimmune, Inc.'s revenue compounded faster (128.0% CAGR vs -59.5%).

Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies, vaccines, and peptide-based therapies. Its pipeline covers infectious disease prevention, liver disease treatments, and metabolic disorder therapies, serving global biopharmaceutical and healthcare markets while advancing candidates through clinical trials.

Universal Health Services, Inc. (UHS) is an American Fortune 500 company that provides hospital and healthcare services, based in King of Prussia, Pennsylvania. In 2024, UHS reported total revenues of $15.8 billion.

ALT vs FCUV — Head-to-Head

Bigger by revenue
FCUV
FCUV
1.4× larger
FCUV
$35.3K
$26.0K
ALT
Growing faster (revenue YoY)
ALT
ALT
+205.5% gap
ALT
420.0%
214.5%
FCUV
More free cash flow
FCUV
FCUV
$66.1M more FCF
FCUV
$-1.4M
$-67.5M
ALT
Faster 2-yr revenue CAGR
ALT
ALT
Annualised
ALT
128.0%
-59.5%
FCUV

Income Statement — Q4 FY2025 vs Q2 FY2025

Metric
ALT
ALT
FCUV
FCUV
Revenue
$26.0K
$35.3K
Net Profit
$-1.5M
Gross Margin
-35.1%
Operating Margin
-4366.7%
Net Margin
-4261.7%
Revenue YoY
420.0%
214.5%
Net Profit YoY
-18.0%
-10.3%
EPS (diluted)

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ALT
ALT
FCUV
FCUV
Q4 25
$26.0K
Q3 25
$5.0K
Q2 25
$5.0K
$35.3K
Q1 25
$5.0K
$190.3K
Q4 24
$5.0K
$133.2K
Q3 24
$5.0K
$74.2K
Q2 24
$5.0K
Q1 24
$5.0K
$179.5K
Net Profit
ALT
ALT
FCUV
FCUV
Q4 25
Q3 25
$-19.0M
Q2 25
$-22.1M
$-1.5M
Q1 25
$-19.6M
$-1.3M
Q4 24
Q3 24
$-22.8M
$1.4M
Q2 24
$-24.6M
Q1 24
$-24.4M
$-1.3M
Gross Margin
ALT
ALT
FCUV
FCUV
Q4 25
Q3 25
Q2 25
-35.1%
Q1 25
16.1%
Q4 24
-95.4%
Q3 24
42.7%
Q2 24
Q1 24
50.3%
Operating Margin
ALT
ALT
FCUV
FCUV
Q4 25
Q3 25
-417180.0%
Q2 25
-458440.0%
-4366.7%
Q1 25
-436300.0%
-668.3%
Q4 24
-1507.4%
Q3 24
-495340.0%
-2353.8%
Q2 24
-534900.0%
Q1 24
-535880.0%
-676.3%
Net Margin
ALT
ALT
FCUV
FCUV
Q4 25
Q3 25
-380280.0%
Q2 25
-442920.0%
-4261.7%
Q1 25
-391500.0%
-657.7%
Q4 24
Q3 24
-456900.0%
1942.9%
Q2 24
-492800.0%
Q1 24
-487880.0%
-732.9%
EPS (diluted)
ALT
ALT
FCUV
FCUV
Q4 25
Q3 25
$-0.21
Q2 25
$-0.27
Q1 25
$-0.26
$-0.17
Q4 24
$-4.57
Q3 24
$-0.32
$0.02
Q2 24
$-0.35
Q1 24
$-0.34
$-0.20

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ALT
ALT
FCUV
FCUV
Cash + ST InvestmentsLiquidity on hand
$273.5M
$1.2M
Total DebtLower is stronger
$34.3M
Stockholders' EquityBook value
$224.9M
$845.6K
Total Assets
$279.9M
$1.7M
Debt / EquityLower = less leverage
0.15×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ALT
ALT
FCUV
FCUV
Q4 25
$273.5M
Q3 25
$210.8M
Q2 25
$183.1M
$1.2M
Q1 25
$149.8M
$2.2M
Q4 24
$131.9M
$3.6M
Q3 24
$139.4M
$5.4M
Q2 24
$164.9M
Q1 24
$182.0M
$114.1K
Total Debt
ALT
ALT
FCUV
FCUV
Q4 25
$34.3M
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Stockholders' Equity
ALT
ALT
FCUV
FCUV
Q4 25
$224.9M
Q3 25
$185.6M
Q2 25
$161.4M
$845.6K
Q1 25
$142.2M
$1.9M
Q4 24
$123.5M
$3.2M
Q3 24
$133.4M
$5.4M
Q2 24
$152.5M
Q1 24
$172.9M
$2.4M
Total Assets
ALT
ALT
FCUV
FCUV
Q4 25
$279.9M
Q3 25
$218.4M
Q2 25
$190.3M
$1.7M
Q1 25
$157.3M
$2.7M
Q4 24
$139.3M
$4.1M
Q3 24
$147.9M
$6.2M
Q2 24
$173.3M
Q1 24
$188.4M
$5.0M
Debt / Equity
ALT
ALT
FCUV
FCUV
Q4 25
0.15×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ALT
ALT
FCUV
FCUV
Operating Cash FlowLast quarter
$-67.5M
$-1.4M
Free Cash FlowOCF − Capex
$-67.5M
$-1.4M
FCF MarginFCF / Revenue
-259792.3%
-4047.4%
Capex IntensityCapex / Revenue
42.3%
4.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-5.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ALT
ALT
FCUV
FCUV
Q4 25
$-67.5M
Q3 25
$-11.9M
Q2 25
$-19.4M
$-1.4M
Q1 25
$-16.8M
$-1.2M
Q4 24
$-79.8M
$-997.9K
Q3 24
$-27.1M
$-1.9M
Q2 24
$-18.1M
Q1 24
$-16.4M
$-892.1K
Free Cash Flow
ALT
ALT
FCUV
FCUV
Q4 25
$-67.5M
Q3 25
Q2 25
$-1.4M
Q1 25
$-1.2M
Q4 24
$-1.0M
Q3 24
$-1.9M
Q2 24
Q1 24
$-897.1K
FCF Margin
ALT
ALT
FCUV
FCUV
Q4 25
-259792.3%
Q3 25
Q2 25
-4047.4%
Q1 25
-653.6%
Q4 24
-753.3%
Q3 24
-2614.6%
Q2 24
Q1 24
-499.8%
Capex Intensity
ALT
ALT
FCUV
FCUV
Q4 25
42.3%
Q3 25
0.0%
Q2 25
4.8%
Q1 25
12.3%
Q4 24
4.1%
Q3 24
4.7%
Q2 24
Q1 24
2.8%
Cash Conversion
ALT
ALT
FCUV
FCUV
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
-1.34×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons